Cargnel Mickaël, Kelly Moira, Imberechts Hein, Catry Boudewijn, Filippitzi Maria-Eleni
Coordination of Veterinary Activities Service, Infectious Diseases in Animals Department, Sciensano, 1050 Brussels, Belgium.
Healthcare-Associated Infections and Antimicrobial Resistance Service, Epidemiology and Public Health Department, Sciensano, 1050 Brussels, Belgium.
Antibiotics (Basel). 2024 Jan 16;13(1):84. doi: 10.3390/antibiotics13010084.
(1) Background. Antimicrobial resistance (AMR) poses a substantial global health threat with profound economic implications. Acknowledging the imperative for a One Health (OH) strategy to combat this menace, Belgium introduced an annual national OH report, known as the "BELMAP report," encompassing antimicrobial use (AMU) and AMR, with the first edition completed in 2021. The integration of innovations for the healthcare system demands a meticulously planned process. (2) Methods. We introduced a three-step stakeholder analysis (SA) as a prospective framework for navigating this new report process, fostering complementary collaboration, pinpointing obstacles, suggesting approaches to overcome them, and facilitating national policy development. The SA unfolds in three steps: stakeholders identify and list their relevant activities, assess their positions regarding the BELMAP report, and complete "actor mapping" of national AMR and AMU stakeholders. (3) Results. Stakeholder identification reveals a fragmented landscape of AMR and AMU activities across Belgium. Assessment of stakeholder positions uncovers diverse expectations, collaborative challenges, and resource considerations. "Actor mapping" identifies key stakeholders, emphasizing the importance of high-interest and high-power actors. (4) Conclusions. This SA approach not only provides insights into the present stakeholder landscape in Belgium, it can also serve as a blueprint for other countries in the process of developing OH reports.
(1) 背景。抗菌药物耐药性（AMR）对全球健康构成了重大威胁，并产生了深远的经济影响。认识到采取“同一个健康”（OH）战略应对这一威胁的紧迫性，比利时发布了一份年度国家OH报告，即“BELMAP报告”，涵盖抗菌药物使用（AMU）和AMR情况，第一版于2021年完成。医疗保健系统创新的整合需要精心规划的过程。(2) 方法。我们引入了一个三步利益相关者分析（SA），作为指导这一新报告流程的前瞻性框架，促进互补性协作，找出障碍，提出克服障碍的方法，并推动国家政策的制定。SA分三步展开：利益相关者识别并列出其相关活动，评估他们对BELMAP报告的立场，并完成国家AMR和AMU利益相关者的“行为者映射”。(3) 结果。利益相关者识别显示，比利时各地的AMR和AMU活动呈现出分散的局面。对利益相关者立场的评估揭示了不同的期望、协作挑战和资源考量。“行为者映射”确定了关键利益相关者，强调了高利益和高权力行为者的重要性。(4) 结论。这种SA方法不仅为了解比利时当前的利益相关者格局提供了见解，还可以作为其他国家在制定OH报告过程中的蓝图。
